When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Doença renal policística

  • Overview
  • Theory
  • Diagnosis
  • Management
  • Follow up
  • Resources
Last reviewed: 12 Oct 2025
Last updated: 10 Jan 2025

Summary

Definition

História e exame físico

Principais fatores diagnósticos

  • história familiar de DRP autossômica dominante (DRPAD) ou doença renal em estágio terminal
  • história familiar de evento cerebrovascular.
  • cistos renais
  • hipertensão
  • dor abdominal/nos flancos
  • hematúria
  • massa abdominal/renal palpável
  • cefaleias
  • disúria, dor suprapúbica, febre
Detalhes completos

Outros fatores diagnósticos

  • sopro cardíaco
  • hérnia abdominal
  • hepatomegalia
  • dor torácica
Detalhes completos

Fatores de risco

  • história familiar de DRP autossômica dominante (DRPAD)
  • história familiar de evento cerebrovascular.
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • ultrassonografia renal
  • tomografia computadorizada (TC) de abdome/pelve
  • RNM de abdome/pelve
  • urinálise/cultura de urina e coloração de Gram
  • eletrólitos séricos, ureia e creatinina
  • perfil lipídico em jejum
  • eletrocardiograma (ECG)
  • TC cranioencefálica
Detalhes completos

Investigações a serem consideradas

  • teste genético
  • ecocardiograma
  • urina de 24 horas
  • TC de dupla energia do abdome/pelve
  • punção lombar e análise do líquido cefalorraquidiano
  • proteína C-reativa
  • tomografia por emissão de pósitrons (PET)
Detalhes completos

Algoritmo de tratamento

AGUDA

doença policística autossômica dominante confirmada

CONTÍNUA

doença renal em estágio terminal

Colaboradores

Autores

Marie C. Hogan, MD, PhD

Consultant

Division of Nephrology

Professor of Medicine

College of Medicine

Mayo Clinic

Rochester

MN

Раскрытие информации

MCH receives research funding from Novartis, and was an investigator participating in tolvaptan clinical trials. MCH is also an author of several references cited in this topic.

Maria Irazabel Mira, MD, PhD

Associate Professor of Medicine, Associate Consultant

Division of Nephrology and Hypertension

Department of Internal Medicine

Mayo Clinic

Rochester

MN

Раскрытие информации

MIM is an author of several references cited in this topic.

Выражение благодарностей

Dr Marie C Hogan and Dr Maria Irazabal Mira would like to gratefully acknowledge Dr Vicente Torres, a previous contributor to this topic.

Disclosures: VT is an author of several references cited in this topic.

Рецензенты

Richard Sandford, PhD, FRCP

Wellcome Trust Senior Fellow in Clinical Research

University Reader in Real Genetics

Honorary Consultant in Medical Genetics

Cambridge

UK

Раскрытие информации

RS declares that he has no competing interests.

Arlene Chapman, MD

Professor of Medicine

Renal Division

Emory University

School of Medicine

Atlanta

GA

Раскрытие информации

Not disclosed.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Список литературы

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Основные статьи

Bergmann C, Guay-Woodford LM, Harris PC, et al. Polycystic kidney disease. Nat Rev Dis Primers. 2018 Dec 6;4(1):50.Полный текст  Аннотация

Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019 Mar 2;393(10174):919-35. Аннотация

Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009 Jan;20(1):205-12.Полный текст  Аннотация

Torres VE, Chapman AB, Devuyst O, et al; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012 Dec 20;367(25):2407-18.Полный текст  Аннотация

Schrier RW, Abebe KZ, Perrone RD, et al; HALT-PKD Trial Investigators. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11;371(24):2255-66. Аннотация

Torres VE, Abebe KZ, Chapman AB, et al; HALT-PKD Trial Investigators. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11;371(24):2267-76. Аннотация

Статьи, указанные как источники

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Doença renal policística images

  • Отличия

    • Doença renal cística adquirida
    • Cisto simples
    • Complexo da esclerose tuberosa
    Больше Отличия

  • Рекомендации

    • Autosomal-dominant polycystic kidney disease (ADPKD): executive summary
    • KHA-CARI autosomal dominant polycystic kidney disease guidelines
    Больше Рекомендации

  • Лифлеты для пациента

    Nefrolitíase

    Infecção renal

    Больше Лифлеты для пациента

  • Calculators

    Taxa de filtração glomerular estimada pela equação de estudo em MDRD rastreável por IDMS

    More Calculators

  • Videos

    Punção lombar diagnóstica em adultos: demonstração animada

    More videos
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer